ALB and Hypoglycemia: The only study evaluating the differential effect of hypoalbuminemia on hypoglycemia in 30 individuals with T2DM treated with Gla-300 and IDeg reported that in those with serum-albumin levels <3.8 g/dL, the mean percentages of time with hypoglycemia (1.9 vs. 11.1; P=0.002), clinically important hypoglycemia (0.02 vs. 3.64, P=0.002), and nocturnal hypoglycemia (1.5 vs. 7.4; P=0.004) were lower in Gla-300 vs. IDeg group [26].